Unlock instant, AI-driven research and patent intelligence for your innovation.
[1,2,4]triazol[1,5-a]pyridine compound as well as preparation method and medical application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of compounds and mixtures, applied in the field of medicine
Active Publication Date: 2018-03-06
NAT INST OF PHARMA R & D CO LTD
View PDF6 Cites 17 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Although a series of JAK inhibitors have been disclosed, there is still a need to develop compounds with better selectivity and efficacy
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0217] Example 1: N-(5-(4-((1,1-dioxothiomorpholine)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine Preparation of -2-yl)-2-oxopyrrolidine-3-carboxamide
[0218]
[0219]
[0220] Step 1: 4-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-benzyl)thiomorpholine 1,1- Synthesis of Dioxide (Intermediate 1A)
[0221] 4-Bromomethylphenylboronic acid pinacol ester (50.00g, 16.84mmol), 1,1-dioxide thiomorpholine (27.36g, 20.24mmol), potassiumcarbonate (27.92g, 20.20mmol) were added to 250 mL of N,N-dimethylformamide was added to the reaction flask, and the reaction was stirred at 80°C for 4 hours. After cooling to room temperature, the reaction solution was poured into 1250 mL of ice water, stirred for 30 minutes, and suction filtered to obtain the title product, 47.2 g of white solid, with a yield of 79.7%.
[0222] Step 2: 4-(4-(2-Amino-[1,2,4]triazolo[1,5-a]pyridin-5-yl)benzyl)thiomorpholine 1,1-dioxide Synthesis of (Intermediate 1B)
[0223] Add 5-bromo-[1,2,4]triazolo[1...
Embodiment 2
[0228]Example 2: N-(5-(4-((1,1-dioxothiomorpholine)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine Preparation of -2-yl)pyrrolidine-2-carboxamide
[0229]
[0230] The same preparation method as in Example 1, except that prolyl chloride (using Boc-L-proline as raw material, reference Tetrahedron, 65 (25), 4841-4845; 2009 preparation) replaces 2-oxo-pyrrolidine -3-Formyl chloride to give the title compound.
[0231] ESI-MS[M+H](m / z):455.1.
[0232] 1 H NMR (300MHz, DMSO): δ10.38(s,1H),7.99(m,2H),7.90(m,1H),7.73(m,2H),7.53(m,2H),7.35(m,1H ),3.89(m,1H),3.73(s,2H),3.40(m,2H),3.13(m,4H),2.94(m,4H),1.74(m,4H).
Embodiment 3
[0233] Example 3: N-(5-(4-((1,1-dioxothiomorpholine)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine Preparation of -2-yl)-1-methylazetidine-3-carboxamide
[0234]
[0235] The preparation method is the same as in Example 1, except that 2-oxo-pyrrolidine- 3-Formyl chloride to give the title compound.
[0236] ESI-MS[M+H](m / z):455.1.
[0237] 1 H NMR(300MHz,DMSO):δ10.45(s,1H),8.01(m,2H),7.88(m,1H),7.72(m,2H),7.49(m,2H),7.36(m,1H ),3.73(s,2H),3.31-3.72(m,4H),3.39(m,1H),3.15(m,4H),2.95(m,4H),2.33(s,3H).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention relates to a [1,2,4]triazol[1,5-a] pyridine compound as well as a preparation method and medical application thereof. Particularly, the invention relates to the compound shown in a general formula I, the preparation method of the compound, a medicinal composition containing the compound and application of the compound as a Janus kinase inhibitor. The compound and the medicinal composition containing the compound can be used for treating diseases related to the activity of Janus kinase, such as inflammation, autoimmune disease and cancer. The definitions of all substituent groupsin the general formula I are identical with those of the description. (The general formula is shown in the description).
Description
technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to a new [1,2,4]triazolo[1,5-a]pyridine compound, its preparation method and a pharmaceutical composition containing it, and its use for regulating Janus kinase (JAK) activity and use for the treatment and / or prevention of diseases associated with JAK activity. Background technique [0002] The intracellularsignal transmission process is an effective way for cells to respond to external stimuli and ultimately trigger specific biological effects. Cytokines can conduct intracellularsignal transmission through a variety of signal transduction pathways, and thus participate in the regulation of many important biological functions related to hematopoietic function and immunity. The Janus kinase (JAK) family of proteintyrosine kinases and the activator of transcription (STAT) play an important role in the process of cytokinesignal transduction. [0003] The Janus kinase ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
![[1,2,4]triazol[1,5-a]pyridine compound as well as preparation method and medical application thereof](https://images-eureka.patsnap.com/patent_img/6068898e-27c2-4f5d-bad3-cdedf7dcddf0/FDA0001381371540000011.png)
![[1,2,4]triazol[1,5-a]pyridine compound as well as preparation method and medical application thereof](https://images-eureka.patsnap.com/patent_img/6068898e-27c2-4f5d-bad3-cdedf7dcddf0/FDA0001381371540000021.png)
![[1,2,4]triazol[1,5-a]pyridine compound as well as preparation method and medical application thereof](https://images-eureka.patsnap.com/patent_img/6068898e-27c2-4f5d-bad3-cdedf7dcddf0/FDA0001381371540000031.png)
Login to View More 
Login to View More 
